COVID-19: Is Omicron a bigger threat than the Delta variant?

What is the Omicron variant of COVID-19?

On November 26th, the World Health Organization (WHO) designated Omicron a variant of concern. This decision was based on the long list of mutations it has, which could impact how easily it is transmitted or the severity of illness it causes.

The WHO recently warned that the variant spreads faster than the Delta strain, adding that vaccines may be less effective against it. "(Omicron) is spreading faster than the Delta variant in South Africa where Delta circulation was low, but also appears to spread more quickly than the Delta variant in other countries where the incidence of the Delta variant is high, such as in the United Kingdom," the organisation said.

Around 4,700 cases of the Omicron variant of COVID-19 have been confirmed in the UK so far, and this week the UK confirmed the first death from the new variant. The rate of Omicron infections is at around 200,000 per day, with the strain expected to become dominant in London within a couple of days.

The UK's coronavirus alert level has been raised from three to four, meaning the transmission of the virus is high and social distancing should be observed. The COVID-19 booster programme has also been ramped up in response to the rapidly spreading Omicron strain.

How is the Omicron variant different to Delta?

"To date, we believe Omicron has more mutations on its spike protein than the Delta variant does," says Rodney E. Rohde, a professor of clinical laboratory science and an infectious disease specialist at Texas State University.

"Early data are suggesting that it may be more transmissible and evidence is showing it is rapidly spreading geographically with at least 50 countries reporting it via WHO. The US Centers for Disease Control and Prevention also reports that at least 30 states and Washington DC have reported it."

Typically, Rohde explains, a virus is already spreading prior to detection, due to the incubation of the virus prior to symptoms. "Many scientists, including those from South Africa where it was first discovered, believe this variant will infect more people who have had COVID-19 and recovered due to these new mutations," he says.

"So, it is critical that we continue to vaccinate the world. Vaccination is showing better coverage and more long-term coverage versus natural infection when it comes to variants."

Patient picks for COVID-19

Chest and lungs

COVID-19 coronavirus: what is an underlying health condition?

As cases of coronavirus continue to rise, it's vital to know who is at greatest risk. People with underlying health conditions are more likely to experience worse symptoms or develop complications if they contract COVID-19 - here doctors explain why.

by Andrea Downey

Chest and lungs

Long COVID

Most people with COVID-19 infection (SARS CoV-2 infection) feel better within a few days or weeks and recover completely within 12 weeks of the infection. However, some people have ongoing symptoms that remain for weeks, months, or longer, which is usually called "long COVID". For some, these long-term effects of COVID-19 can be debilitating. These effects can be very different from person to person, and it seems likely that there are different 'types' of long COVID, or different syndromes, which might behave in different ways.

by Dr Doug McKechnie, MRCGP

Is Omicron a bigger threat than previous COVID-19 variants?

Ultimately, Rodhe says, it is too early to tell. However, some small studies are being completed and published which paint a concerning picture of the impact Omicron may have. "One study indicates Omicron found a significant drop in how well vaccine-elicited antibodies target the Omicron variant of coronavirus," he says.

"However, the variant didn't completely dodge vaccination. Limitations of the study were it did not include people who had received booster doses. The study also suggests that people who were previously infected and then vaccinated, or people who've had boosters, should maintain greater levels of protection even against Omicron," adds Rohde.

"Most of these studies have a small sample size without much diversity so generalisation to large populations should be cautioned at this time."

Due to the changes to Omicron's spike protein - which plays an important role in how the virus infects the host - it is believed our current vaccines may be less effective against the variant.

Research released recently by the UK Health Security Agency found that a full two-dose vaccination course was less effective against symptomatic disease with Omicron than with the original strain of COVID-19 or the Delta variant. However, it also found that a booster dose prevents about 75% of people from getting any COVID-19 symptoms.

Another preliminary study by the Africa Health Research Institute, published on 7th December, found there was a 41-fold reduction in the potency of antibodies against Omicron after two doses of the Pfizer vaccine.

Vaccine developers and manufacturers have said that they will continue with plans to develop an updated Omicron-based vaccine, which should be available by March 2022 if necessary.

What are we yet to know for certain about the Omicron variant?

"Scientists in South Africa as well as globally are working, as fast as they are able to, to try to be able to discover more about a newly identified strain of the COVID-19 virus," says Rohde. "While I and others continue to share our thoughts about early research as well as past experience, we still have much to learn."

Ultimately, researchers still don’t know for certain how easily Omicron is transmitted, the severity of infection and symptoms and whether the variant can successfully evade our current vaccines. "We also need to know more about reinfection variables, booster protection and other virulence data," he adds.